Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of STERIS plc (NYSE:STE)

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of STERIS plc (NYSE:STE). In a filing disclosed on May 08th, the Representative disclosed that they had bought between $1,001 and $15,000 in STERIS stock on May 1st. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Revvity (NYSE:RVTY) on 5/1/2026.
• Sold $1,001 – $15,000 in shares of Flex (NASDAQ:FLEX) on 5/1/2026.
• Purchased $1,001 – $15,000 in shares of LPL Financial (NASDAQ:LPLA) on 5/1/2026.
• Purchased $1,001 – $15,000 in shares of FirstService (NASDAQ:FSV) on 5/1/2026.
• Sold $1,001 – $15,000 in shares of SS&C Technologies (NASDAQ:SSNC) on 5/1/2026.
• Purchased $1,001 – $15,000 in shares of Wayfair (NYSE:W) on 5/1/2026.
• Purchased $1,001 – $15,000 in shares of DoorDash (NASDAQ:DASH) on 5/1/2026.
• Purchased $1,001 – $15,000 in shares of Sensata Technologies (NYSE:ST) on 5/1/2026.
• Purchased $1,001 – $15,000 in shares of Veralto (NYSE:VLTO) on 5/1/2026.
• Purchased $1,001 – $15,000 in shares of BridgeBio Pharma (NASDAQ:BBIO) on 4/29/2026.

STERIS Stock Performance

Shares of NYSE:STE traded up $10.76 during midday trading on Tuesday, hitting $212.61. The company’s stock had a trading volume of 1,062,608 shares, compared to its average volume of 775,769. The stock has a market capitalization of $20.85 billion, a price-to-earnings ratio of 29.62 and a beta of 0.95. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.75 and a current ratio of 2.48. STERIS plc has a fifty-two week low of $195.14 and a fifty-two week high of $269.44. The stock’s 50 day simple moving average is $222.37 and its 200 day simple moving average is $243.74.

STERIS (NYSE:STE) last issued its earnings results on Monday, May 11th. The medical equipment provider reported $2.83 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.86 by ($0.03). The firm had revenue of $1.59 billion during the quarter, compared to analyst estimates of $1.59 billion. STERIS had a net margin of 12.15% and a return on equity of 14.34%. The company’s revenue for the quarter was up 6.7% on a year-over-year basis. During the same quarter last year, the business posted $2.74 earnings per share. STERIS has set its FY 2027 guidance at 11.100-11.300 EPS. As a group, research analysts anticipate that STERIS plc will post 10.22 earnings per share for the current year.

STERIS Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 26th. Stockholders of record on Monday, June 8th will be paid a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 1.2%. The ex-dividend date is Monday, June 8th. STERIS’s dividend payout ratio is 35.15%.

Key Stories Impacting STERIS

Here are the key news stories impacting STERIS this week:

• Positive Sentiment: STERIS issued fiscal 2027 EPS guidance of $11.10–$11.30, above Wall Street expectations, and also forecast revenue growth of 7%–8%, signaling continued demand for its sterilization and medical equipment businesses.
• Positive Sentiment: The board approved a new $1 billion share repurchase program, which can support the stock by reducing share count over time and suggesting management sees value in the shares.
• Positive Sentiment: Full-year fiscal 2026 revenue from continuing operations rose 9% to $5.9 billion, with 7% organic constant-currency growth, showing the core business is still expanding.
• Neutral Sentiment: The company missed fourth-quarter earnings and revenue estimates by a small margin, reporting $2.83 EPS versus $2.86 expected and revenue of $1.59 billion versus roughly $1.61 billion expected.
• Neutral Sentiment: Recent institutional and congressional trading data is mixed, with several hedge funds reducing positions but some notable buyers and multiple congressional purchases; these flows are not likely the main driver of today’s move.

Insider Transactions at STERIS

In other news, Director Cynthia L. Feldmann sold 3,098 shares of the business’s stock in a transaction on Thursday, March 5th. The shares were sold at an average price of $237.21, for a total value of $734,876.58. Following the transaction, the director owned 705 shares of the company’s stock, valued at approximately $167,233.05. The trade was a 81.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 1.07% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on STE shares. Wall Street Zen lowered shares of STERIS from a “strong-buy” rating to a “buy” rating in a research note on Sunday, April 26th. Weiss Ratings lowered shares of STERIS from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday, April 16th. Five analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $275.20.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of STE. Vanguard Group Inc. raised its holdings in STERIS by 0.6% in the 4th quarter. Vanguard Group Inc. now owns 12,286,535 shares of the medical equipment provider’s stock valued at $3,114,882,000 after acquiring an additional 73,014 shares in the last quarter. State Street Corp increased its stake in STERIS by 6.0% in the 4th quarter. State Street Corp now owns 4,614,840 shares of the medical equipment provider’s stock valued at $1,169,957,000 after buying an additional 260,001 shares during the last quarter. Geode Capital Management LLC boosted its holdings in STERIS by 0.6% in the 4th quarter. Geode Capital Management LLC now owns 2,523,620 shares of the medical equipment provider’s stock worth $637,259,000 after buying an additional 14,151 shares during the period. Orbis Allan Gray Ltd lifted its stake in STERIS by 5.6% in the 4th quarter. Orbis Allan Gray Ltd now owns 2,249,511 shares of the medical equipment provider’s stock worth $570,296,000 after purchasing an additional 120,200 shares in the last quarter. Finally, AQR Capital Management LLC grew its holdings in STERIS by 37.2% in the 4th quarter. AQR Capital Management LLC now owns 1,623,234 shares of the medical equipment provider’s stock worth $411,522,000 after acquiring an additional 440,164 shares during the last quarter. Hedge funds and other institutional investors own 94.69% of the company’s stock.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About STERIS

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.